Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Dimitra Apessou
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Dimitra Apessou wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm. 2014

Karakaxas, Dimitrios / Gazouli, Maria / Liakakos, Theodoros / Vaiopoulou, Anna / Apessou, Dimitra / Papaparaskeva, Kleo / Patapis, Pavlos / Dervenis, Christos. ·aSurgical Department-HPB Surgical Unit, Konstantopouleion Agia Olga General Hospital bLaboratory of Biology, Department of Basic Medical Science, School of Medicine, University of Athens cThird Department of Surgery, University of Athens School of Medicine, Attikon University Hospital, Athens, Greece. ·Eur J Gastroenterol Hepatol · Pubmed #24987821.

ABSTRACT: Pancreatic neuroendocrine tumors (PNETs) share a unique genetic identity, functional behavior, and clinical course. Compared with tumors of the exocrine pancreas, they are rare and show a different biologic behavior and prognosis. On the basis of data from recent studies, all PNETs, outside of small insulinomas, should be considered potentially malignant and treated accordingly. Untreated tumors have a high possibility to grow locally into adjacent structures or spread to distant organs. Although surgical excision irrespective of tumor functioning or nonfunctioning state remains the cornerstone of therapy, providing the best disease-free and survival rates to date, the understanding of the genetic nature of the disease yields new 'targets' to consider in drug development. The aim of this review is to summarize all recent advances of genetic research and new drug development in terms of PNETs, especially their genetic identity and subsequent alterations leading to the development of near or total malignant activity, and the new medical treatment strategies of this potentially curable disease on the basis of therapeutical agents acting, where possible, at the genetic level.

2 Article Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). 2019

Zarkavelis, George / Kotoula, Vassiliki / Kolliou, Georgia-Angeliki / Papadopoulou, Kyriaki / Tikas, Ioannis / Karavasilis, Vasilios / Samantas, Epaminontas / Dervenis, Christos / Efstratiou, Ioannis / Nicolaou, Irene / Apessou, Dimitra / Kafiri, Georgia / Koletsa, Triantafyllia / Bompolaki, Iliada / Rallis, Grigorios / Batistatou, Anna / Glantzounis, George / Pectasides, Dimitrios / Fountzilas, George / Pentheroudakis, George. ·Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece. · Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece. · Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece. · Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece. · Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, Greece. · Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece. · Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece. · First Department of Surgery, General Hospital Konstantopouleio Agia Olga, Athens, Greece. · Department of Pathology, Papageorgiou Hospital, Thessaloniki, Greece. · Department of Histopathology, Agii Anagriri Hospital, Athens, Greece. · Department of Pathology, General Hospital Konstantopouleio Agia Olga, Athens, Greece. · Department of Pathology, Hippokration Hospital, Athens, Greece. · Oncology Department, General Hospital of Chania, Crete, Greece. · Department of Pathology, Ioannina University Hospital, Ioannina, Greece. · Department of Surgery, Medical School, University of Ioannina, Ioannina, Greece. · Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece. · Aristotle University of Thessaloniki, Thessaloniki, Greece. ·ESMO Open · Pubmed #31673425.

ABSTRACT: Pancreatic cancer is one of the most fatal malignancies ranking fourth among the leading causes of cancer death with diagnosis at late stages carrying a dismal prognosis. The aim of our retrospective study was to describe the nature and the incidence of gene mutations and genomic instability in advanced pancreatic adenocarcinomas of a Greek patient population fully annotated with clinicopathological data. We used a targeted next-generation sequencing (NGS) panel encompassing genes commonly mutated in pancreatic tumours in a patient population managed with either nab-paclitaxel regimens or targeted compounds modulating the epidermal growth factor receptor (EGFR)/AKT/mTOR axis. We identified